BRAF and central nervous system cancer: Because genetic alterations are important in tumor development and progression (33, 34) and both BRAFV600E and BRAFAMP can activate the MAPK pathway, we investigated the different effects of these two BRAF alterations and the mutations associated on the survival of glioma patients.